Repeatability of brown adipose tissue activation measured by [<SUP>18</SUP>F]FDG PET after beta3-adrenergic stimuli in a mouse model
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
NUCLEAR MEDICINE AND BIOLOGY, v.126, article ID 108390, 5p, 2023
Resumo
This study aimed to evaluate the repeatability of brown adipose tissue (BAT) activation measured by [F-18]FDG-PET after beta3-adrenergic stimuli with CL316243 in mice.Methods: Male C57BL/6 mice underwent [F-18]FDG-PET at baseline without stimulation (T0-NS), on three consecutive days after intravenous administration of the selective beta 3-adrenergic agonist CL316243 (T1-CL, T2-CL, T3-CL), and without stimuli after 1 and 2 weeks (T7-NS and T14-NS). The standardized uptake value (SUVmax), BAT metabolic volume (BMV), and total BAT glycolysis (TBG) were measured in each scanning session, with statistical groupwise comparisons by ANOVA and post hoc Tukey test.Results: SUVmax, BMV, and TBG values showed no significant differences between the three PET scans without stimuli, but were significantly higher after CL316243 administration (p < 0.0001). The mean coefficient of variation (CoV) of PET within individuals was 49 % at baseline but only 9 % with pharmacological stimulation.Conclusions: The study demonstrated that administration of the selective beta 3-adrenergic receptor agonist CL316243 (CL) in mice leads to consistent metabolic activation of brown adipose tissue (BAT), as measured by [F-18]FDG-PET. We also demonstrated metabolic activation by repeated pharmacological challenge, without evidence of hysteresis. Thus, the methods used in the current work should serve for further studies on BAT metabolism in experimental animals, with translational value for clinical research.
Palavras-chave
Positron emission tomography, Brown adipose tissue, [F-18]FDG, beta3-adrenergic stimuli
Referências
- Au-Yong ITH, 2009, DIABETES, V58, P2583, DOI 10.2337/db09-0833
- Bahler L, 2016, J APPL PHYSIOL, V120, P1418, DOI 10.1152/japplphysiol.00008.2016
- Blondin DP, 2020, CELL METAB, V32, P287, DOI 10.1016/j.cmet.2020.07.005
- Carpentier AC, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00447
- Chen KY, 2016, CELL METAB, V24, P210, DOI 10.1016/j.cmet.2016.07.014
- Crandall JP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214765
- Crane JD, 2014, MOL METAB, V3, P490, DOI 10.1016/j.molmet.2014.04.007
- Cypess AM, 2015, CELL METAB, V21, P33, DOI 10.1016/j.cmet.2014.12.009
- Cypess AM, 2013, J NUCL MED, V54, P1896, DOI 10.2967/jnumed.113.121012
- Eriksson O, 2015, J NUCL MED, V56, P1937, DOI 10.2967/jnumed.115.156422
- Faria DD, 2023, NUCL MED BIOL, V122, DOI 10.1016/j.nucmedbio.2023.108362
- Fraum TJ, 2019, CELL METAB, V30, P212, DOI 10.1016/j.cmet.2019.05.019
- Hanssen MJW, 2016, DIABETES, V65, P1179, DOI 10.2337/db15-1372
- Keijer J, 2019, MOL METAB, V25, P168, DOI 10.1016/j.molmet.2019.04.001
- Lodge MA, 2017, J NUCL MED, V58, P523, DOI 10.2967/jnumed.116.186353
- Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877
- Medak KD, 2022, PHYSIOL REP, V10, DOI 10.14814/phy2.15187
- Mirbolooki MR, 2014, NUCL MED BIOL, V41, P10, DOI 10.1016/j.nucmedbio.2013.08.009
- Muzik O, 2017, J NUCL MED, V58, P799, DOI 10.2967/jnumed.116.180992
- Olsen JM, 2019, MOL METAB, V30, P240, DOI 10.1016/j.molmet.2019.10.004
- Ong FJ, 2018, CLIN SCI, V132, P1039, DOI 10.1042/CS20170276
- Ran CZ, 2018, MOL IMAGING BIOL, V20, P188, DOI 10.1007/s11307-017-1129-z
- Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x
- Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949
- Wang XK, 2012, JOVE-J VIS EXP, DOI 10.3791/4060
- YOSHIDA T, 1994, LIFE SCI, V54, P491, DOI 10.1016/0024-3205(94)00408-0
- Zhang F, 2018, CELL METAB, V27, P252, DOI 10.1016/j.cmet.2017.12.004